News Releases

ELIAS Animal Health adds to leadership team to support additional clinical studies and commercialization, $5 million capital raise nearly complete

by ELIAS Animal Health | Feb 19, 2020

To support the company’s continuing growth, pursuit of USDA licensure and commercialization in 2020, ELIAS Animal Health has hired Evan Courtemanche as Vice President of Manufacturing, and Jody Ehrhardt, as Director of Clinical Studies.

Evan Courtemanche brings an extensive background in mammalian cell-culture manufacturing and supply chain functions in FDA and USDA-regulated therapeutics, and managing contract manufacturing relationships, both international and domestic. He currently oversees the biologics manufacturing processes and facility where the company’s USDA-regulated cancer immunotherapy is manufactured. Previously, Mr. Courtemanche served in manufacturing leadership and oversight roles for Aratana Therapeutics and Genzyme. Mr. Courtemanche has a BA in Biology from University of Pennsylvania and a MS in Biotechnology from Northeastern University in Boston, MA.

Jody Ehrhardt, CCRC, brings more than 25 years of experience in clinical studies in both human and animal sciences. As the Director of Clinical Studies for ELIAS, she manages clinical study development, including protocol composition, study site recruitment and management, and regulatory reporting. Previously, Ms. Ehrhardt served as a clinical research consultant for CEVA Animal Health and Psychiatry Associates of Kansas City. Ms. Ehrhardt has a Medical Assistant diploma from Concord Career Institute, Clinical Research Administration credits from George Washington School of Medicine and currently serves as Vice President of the Association of Clinical Research Professionals local chapter.

With the addition of these critical team members, ELIAS is preparing to launch a larger clinical study in the spring of 2020 to pursue licensure of its cancer immunotherapy (ECI®) treatment as an alternative to chemotherapy for dogs diagnosed with osteosarcoma, a deadly form of bone cancer. In a preliminary clinical study, the median survival time was 415 days, compared to 270-300 days for traditional chemotherapy treatments, suggesting that ECI holds the potential to significantly improve survival times and quality of life for the canine patient.

This year, ELIAS is also expanding commercial access to its immunotherapy due to the limited treatment options currently available. ECI is distributed as an experimental product under USDA 9 CFR 103.3. Certified treatment centers are listed at ELIASAnimalHealth.com/Available-Locations.

All this progress was made possible by a $5 million funding round launched in late 2019, which is already more than 80% subscribed by the Company’s existing angel investors. More than half of the proceeds from this round were received in 2019 and the remaining proceeds are expected to be received in first quarter 2020.

Share

Search

Archive

Tweet @AHCorridor

Media Coverage

Inside the Corridor

KC Animal Health Blog

Investment Forum